The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

Inclusion Criteria:

• Body mass index between 18 and 30 kilograms/meter squared inclusive, at the screening visit.
• Japanese participants must be of Japanese descent (both biological parents are ethnically Japanese).
• Caucasian participants must be of European or Latin American Caucasian descent.
• A female participant is eligible to participate if she is a woman of nonchildbearing potential as defined in the protocol.
• Males who are sexually active with woman of childbearing potential must agree to follow protocol-defined instructions for method(s) of contraception.

Exclusion Criteria:

• Any acute or chronic medical illness.
• Active infection, including with coronavirus disease-19, diagnosed clinically by the investigator.
• History of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or sponsor clinical trial physician, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

Note: Other protocol-defined inclusion/exclusion criteria apply.